Indivior PLC (LON:INDV) had its price objective lowered by equities researchers at Deutsche Bank AG from GBX 400 ($5.22) to GBX 395 ($5.16) in a research report issued to clients and investors on Tuesday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s price objective points to a potential upside of 25.52% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Jefferies Group reaffirmed a “buy” rating and set a GBX 245 ($3.20) price target on shares of Indivior PLC in a research report on Monday, June 6th. Stifel Nicolaus upped their price target on shares of Indivior PLC from GBX 310 ($4.05) to GBX 350 ($4.57) and gave the company a “buy” rating in a research report on Monday, July 11th. Finally, Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 340 ($4.44) price target on shares of Indivior PLC in a research report on Friday, July 29th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of GBX 345.71 ($4.51).

Analyst Recommendations for Indivior PLC (LON:INDV)

Indivior PLC (LON:INDV) traded down 0.0318% during trading on Tuesday, hitting GBX 313.2011. 2,989,538 shares of the stock were exchanged. The firm’s market capitalization is GBX 2256.92 billion. Indivior PLC has a 1-year low of GBX 126.60 and a 1-year high of GBX 365.00. The company has a 50-day moving average price of GBX 318.80 and a 200 day moving average price of GBX 239.46.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Indivior PLC Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia.

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with's FREE daily email newsletter.